Centchroman: A non-steroidal anti-fertility agent with anti-hormonal properties.Embryo Implantation, Delayed: Delay in the attachment and implantation of BLASTOCYST to the uterine ENDOMETRIUM. The blastocyst remains unattached beyond the normal duration thus delaying embryonic development.Nictitating Membrane: A fold of the mucous membrane of the CONJUNCTIVA in many animals. At rest, it is hidden in the medial canthus. It can extend to cover part or all of the cornea to help clean the CORNEA.Bronchial Spasm: Spasmodic contraction of the smooth muscle of the bronchi.Contraceptives, Oral: Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both.Ovulation: The discharge of an OVUM from a rupturing follicle in the OVARY.Sterilization, Tubal: Procedures that render the female sterile by interrupting the flow in the FALLOPIAN TUBE. These procedures generally are surgical, and may also use chemicals or physical means.Sterilization Reversal: Procedures to reverse the effect of REPRODUCTIVE STERILIZATION and to regain fertility. Reversal procedures include those used to restore the flow in the FALLOPIAN TUBE or the VAS DEFERENS.Sterilization, Reproductive: Procedures to block or remove all or part of the genital tract for the purpose of rendering individuals sterile, incapable of reproduction. Surgical sterilization procedures are the most commonly used. There are also sterilization procedures involving chemical or physical means.Encyclopedias as Topic: Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)Fallopian Tubes: A pair of highly specialized muscular canals extending from the UTERUS to its corresponding OVARY. They provide the means for OVUM collection, and the site for the final maturation of gametes and FERTILIZATION. The fallopian tube consists of an interstitium, an isthmus, an ampulla, an infundibulum, and fimbriae. Its wall consists of three histologic layers: serous, muscular, and an internal mucosal layer lined with both ciliated and secretory cells.Anesthesia, Spinal: Procedure in which an anesthetic is injected directly into the spinal cord.Ligation: Application of a ligature to tie a vessel or strangulate a part.Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.Abortion, Induced: Intentional removal of a fetus from the uterus by any of a number of techniques. (POPLINE, 1978)Abortifacient Agents, Steroidal: Steroidal compounds with abortifacient activity.Abortifacient Agents, Nonsteroidal: Non-steroidal chemical compounds with abortifacient activity.Abortifacient Agents: Chemical substances that interrupt pregnancy after implantation.Clopenthixol: A thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.IndiaAppendix: A worm-like blind tube extension from the CECUM.Cosmetics: Substances intended to be applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance without affecting the body's structure or functions. Included in this definition are skin creams, lotions, perfumes, lipsticks, fingernail polishes, eye and facial makeup preparations, permanent waves, hair colors, toothpastes, and deodorants, as well as any material intended for use as a component of a cosmetic product. (U.S. Food & Drug Administration Center for Food Safety & Applied Nutrition Office of Cosmetics Fact Sheet (web page) Feb 1995)Vasectomy: Surgical removal of the ductus deferens, or a portion of it. It is done in association with prostatectomy, or to induce infertility. (Dorland, 28th ed)Vasovasostomy: Surgical anastomosis or fistulization of the spermatic ducts to restore fertility in a previously vasectomized male.Social Marginalization: Individuals or groups, excluded from participation in the economic, social, and political activities of membership in a community.Microsurgery: The performance of surgical procedures with the aid of a microscope.Sperm Count: A count of SPERM in the ejaculum, expressed as number per milliliter.Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.Contraceptives, Oral, Combined: Fixed drug combinations administered orally for contraceptive purposes.Contraceptives, Oral, Synthetic: Oral contraceptives which owe their effectiveness to synthetic preparations.Contraceptive Agents, Female: Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading.Desogestrel: A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents.Implants, Experimental: Artificial substitutes for body parts and materials inserted into organisms during experimental studies.Australia: The smallest continent and an independent country, comprising six states and two territories. Its capital is Canberra.Amenorrhea: Absence of menstruation.Skin Irritancy Tests: Tests or bioassays that measure the skin sensitization potential of various chemicals.Mestranol: The 3-methyl ether of ETHINYL ESTRADIOL. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL CONTRACEPTIVES.Multiphasic Screening: The simultaneous use of multiple laboratory procedures for the detection of various diseases. These are usually performed on groups of people.Progestins: Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.Norethynodrel: A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and endometriosis. As a contraceptive, it has usually been administered in combination with MESTRANOL.Algestone Acetophenide: A progesterone that has been used in ESTRUS SYNCHRONIZATION and has been evaluated as an injectable contraceptive in combination with estradiol enanthate. It is also used therapeutically as a topical anti-inflammatory and is applied topically in the treatment of ACNE.Hydroxyprogesterones: Metabolites or derivatives of PROGESTERONE with hydroxyl group substitution at various sites.Medroxyprogesterone Acetate: A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.Estradiol: The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.Algestone: A synthetic progestational dihydroxy derivative of PROGESTERONE. Its acetonide possesses anti-inflammatory properties.Medroxyprogesterone: (6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione. A synthetic progestational hormone used in veterinary practice as an estrus regulator.Intrauterine Devices, Medicated: Intrauterine devices that release contraceptive agents.KansasSocial Welfare: Organized institutions which provide services to ameliorate conditions of need or social pathology in the community.Drug Implants: Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug.

Antimutagenic effects of centchroman--a contraceptive and a candidate drug for breast cancer in multiple mutational assays. (1/5)

Centchroman (CC), a non-steroidal oral contraceptive and a candidate drug for breast cancer, has been reported to exhibit partial to complete remission of lesions in 40.5% of breast cancer patients. The potent anti-oestrogenic activity, negligible side-effects and anti-breast cancer activity of CC prompted us to evaluate the antimutagenic effects of this compound in a bacterial mutagenicity assay and CHO/HPRT and AS52/GPT mutation assays in vitro and in vivo in female Swiss albino mice as measured by both sister chromatid exchange (SCE) and chromosome aberrations (CA) against three known positive mutagen compounds, dimethylbenz[a]anthracene (DMBA), cyclophosphamide (CP) and mitomycin C (MMC). Antimutagenicity assays in Salmonella strains TA97a, TA100, TA98 and TA102 were carried out against commonly used known positive mutagens, sodium azide, 4-nitro-o-phenylenediamine, cumine hydroperoxide, 2-aminofluorene and danthron. A significantly reduced number of bacterial histidine revertant colonies was observed in the plates treated with 0.1, 1, 5 and 10 microg/plate CC and a positive compound when compared with bacterial plates treated with the respective positive compound alone. Ethyl methanesulfonate (EMS), a commonly used positive mutagen for CHO/HPRT and AS52/GPT gene mutation assays, was used for antimutagenicity assay in these cells. CC exhibited protective effects against the mutagenicity of EMS in these two mammalian cell mutation assays, CHO/HPRT and AS52/GPT. In the in vivo studies, pretreatment with CC reduced DMBA-induced SCE and CA and CP- and MMC-induced CA when compared with the group treated only with the positive compounds. These results indicate that CC can reduce the mutagenic effects of known genotoxic compounds.  (+info)

Polyphenols sensitization potentiates susceptibility of MCF-7 and MDA MB-231 cells to Centchroman. (2/5)

 (+info)

Effect of centchroman on tubal transport and preimplantation embryonic development in rats. (3/5)

A single oral administration of centchroman (1.25 mg/kg) to adult female rats within 24 h of mating induced slight acceleration in the rate of transport of embryos through the oviducts. The compound did not seem to produce any deleterious effect on preimplantation embryonic development since well organized and apparently normal embryos were collected from the genital tract up to Day 12 of pregnancy. The recovery rate of embryos from centchroman-treated rats was, however, significantly reduced after Day 4 of pregnancy. There was some stimulation in the rate of cleavage of embryos and morula to blastocyst transformation, but retardation in the shedding of the zona pellucida. The rate of blastocyst formation was not altered when 6-8-cell embryos collected from the oviducts of control rats were transferred to the uteri of control or centchroman-treated females. A delay in zona shedding was observed in the centchroman-treated recipients.  (+info)

Viability and development of 'tube-locked' mouse embryos. (4/5)

'Tube-locked' morulae and blastocysts were recovered from the ampulla of the oviduct of centchroman-treated mice between Days 4 and 12 post coitum and transferred to the uteri of pseudopregnant female mice. Pregnancy and implantation rates were lower and the post-implantation resorption rate was higher in the treated than in the control group. There was little difference in the pregnancy or implantation rates between embryos recovered on Days 4 or 12 post coitum, but the resorption rate increased with increasing duration of embryos in the oviducts and was 100% for the Day-12 embryos. The resorption rate was similar even when these embryos were transferred to the sterile uterine horn of unilaterally pregnant mice. Centchroman did not produce any deleterious effect on embryos which survived until Day 19 of pregnancy in foster mothers. The average fetal weight was also comparable to those of control fetuses.  (+info)

Duration of anti-implantation action of the triphenylethylene anti-oestrogen centchroman in adult female rats. (5/5)

The duration of the anti-implantation action of a single oral post-coital dose (1.25 mg kg-1) of a triphenylethylene anti-oestrogen, centchroman, was determined in adult rats. The effects of centchroman were compared with those of tamoxifen. In rats undergoing delay, centchroman administered orally on day 7 post-coitum prevented the induction of implantation of delayed blastocysts by an implantation inducing dose (1 micrograms per rat, s.c.) of oestrone which was administered earlier than 120 h after centchroman treatment. In tamoxifen (0.2 mg kg-1, orally) pretreated rats, oestrone administered at 144 h or later induced implantation. In cyclic rats treated with centchroman at intervals of 168 h and mated with males of proven fertility, implantation was prevented only when the interval between centchroman treatment and nidatory oestrogen secretion was less than 120 h. None of the females conceived when treated regularly at intervals of 120 h during exposure to fertile males. Discontinuation of treatment resulted in the occurrence of normal implantations in rats that mated 48 h or later after the last dose of centchroman, since in these animals the interval between anti-oestrogen treatment and nidatory oestrogen secretion was greater than 120 h. These findings suggest that the duration of the anti-implantation action of a single oral antifertility dose of centchroman in rats is about 120 h. Recovery of normal blastocysts from rats treated continuously with this dose of centchroman at these intervals suggests lack of significant effect on follicular maturation, ovulation, fertilization, preimplantation development or mating behaviour.(ABSTRACT TRUNCATED AT 250 WORDS)  (+info)

Why buy Saheli 30mg (Centchroman)?. Saheli contains Centchroman as its active ingredient. Centchroman is the worlds first non-steroidal contraceptive pill in the market known to prevent pregnancy. Unlike other birth control pill, Saheli doesnt contain any hormones. Instead, it prevents pregnancy by blocking the estrogen hormone. Saheli 30 mg is manufactured by Hindustan Latex Ltd. You can buy this pill here at a very affordable price.. How does Saheli 30mg (Centchroman) work?. Saheli 30mg (Centchroman) is a non-steroidal contraceptive pill with a weak estrogenic and a potent anti-estrogenic action. The active ingredient of this medication works by blocking the action of estrogen in the uterus. Blocking the action of the estrogen hormone alters the lining of the uterus which prevents the egg from being implanted in the uterus. Normal ovulatory cycle still occurs because the pill did not affect the endocrine system.. How to use Saheli 30mg (Centchroman)?. The usual recommended dose of Saheli ...
The goal of the present study was to test the selectivity of oligomeric pentameric procyanidin from cocoa (pentamer) against a panel of human breast cancer cells and to examine the molecular mechanism(s) by which it causes G0/G1 cell cycle arrest in these cells (12). This is, to our knowledge, the first demonstration that pentamer selectively inhibits growth of human breast cancer cell lines independent of their p53 or estrogen receptor status, whereas normal HMECs and nontransformed, immortalized MCF-10A cells are highly resistant. The resistance of normal HMECs to pentamers cytotoxicity relative to highly sensitive human breast cancer cells is significant because it could serve as a basis for in vivo evaluation of pentamer as a potential chemopreventive and chemotherapeutic agent in both animal models and human disease.. We first evaluated whether pentamers inhibitory effects involve depolarization of the mitochondrial membrane. The MDA MB-231 cells were highly sensitive, whereas the ...
Free Online Library: New candidate drug stops cancer metastasis and regenerates nerve cells. by Asian News International; News, opinion and commentary General interest Cancer Care and treatment Drug therapy Cancer metastasis Cancer treatment G proteins Metastasis Neurons
KineMed, Inc., a pathway-based drug discovery and development company, and Bayer Healthcare AG announced today that they have signed an agreement to discover ne
Genervon disclosed a list of 89 genes associated with ALS whose activity is modulated by its candidate drug GM6, designed to restore neuronal function.
STUDY QUESTION: To what extent do patient- and treatment-related factors explain the variation in morphokinetic parameters proposed as embryo viability markers?. SUMMARY ANSWER: Up to 31% of the observed variation in timing of embryo development can be explained by embryo origin, but no single factor elicits a systematic influence.. WHAT IS KNOWN ALREADY: Several studies report that culture conditions, patient characteristics and treatment influence timing of embryo development, which have promoted the perception that each clinic must develop individual models. Most of the studies have, however, treated embryos from one patient as independent observations, and only very few studies that evaluate the influence from patient- and treatment-related factors on timing of development or time-lapse parameters as predictors of viability have controlled for confounding, which implies a high risk of overestimating the statistical significance of potential correlations.. STUDY DESIGN, SIZE, DURATION: ...
Medivir Nominates MIV-828 as a Candidate Drug for the Treatment of Hematological Malignancies PR Newswire STOCKHOLM, Sweden, Nov. 21, 2018 STOCKHOLM, Sweden, Nov. 21, 2018 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV-828 has been nominated as...
The U.S. Food and Drug Administration has approved a genetic test designed to evaluate whether a person with breast cancer is a good candidate for treatment wit
Methods and compositions for modeling the transcriptional responsiveness of an organism to a candidate drug involve (a) detecting reporter gene product signals from each of a plurality of different, s
Vol 8: Genes associated with genotype-specific DNA methylation in squamous cell carcinoma as candidate drug targets.. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Tamoxifen is both the most widely prescribed drug for breast cancer and preventative therapy worldwide. It is a synthetic derivative of triphenylethylene but was originally screened in a drug development program oriented toward discovering new post-coital contraceptive agents.
It happens all the time: a pharmaceutical or biotechnology company will spend ten years and hundreds of millions of dollars on a drug candidate that looks spectacular in animal models of a disease, only to see it fail during clinical trials, either because of unexpected adverse reactions in a small number of patients or a surprising lack of efficacy. For every drug that is approved, on average more than 6,000 new chemical substances are created. Only seven of these ever end up being tested in humans, and only three make it to Phase III clinical trials, the final step before... ...
BioWorld Online is the news service of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date on all of the industrys business, science and regulatory news -- mergers and collaborations, FDA hearings and results, breakthroughs in research and much more.
Toremifine is an anti-oestrogen hormone that is used in the treatment of breat cancer. Read more about toremifine online at Patient
The major challenge during preformulation is to gain the greatest possible knowledge about candidate drug compounds with minimal use of resources. The
milameline: a candidate drug for the treatment of age-related disorders of cognition; RN refers to the E-isomer; structure given in first source
We have assessed the pharmacokinetics, pharmacological and anti-tumour effects of the specific steroidal anti-oestrogen ICI 182780 in 19 patients with advanced breast cancer resistant to tamoxifen. The agent was administered as a monthly depot intramuscular injection. Peak levels of ICI 182780 occurred a median of 8-9 days after dosing and then declined but were above the projected therapeutic threshold at day 28. Cmax during the first month was 10.5 ng/ml-1 and during the sixth month was 12.6 ng ml-1. The AUCs were 140.5 and 206.8 ng day ml-1 on the first and sixth month of dosing respectively, suggesting some drug accumulation. Luteinising hormone (LH) and follicle-stimulating hormone (FSH) levels rose after withdrawal of tamoxifen and then plateaued, suggesting no effect of ICI 182780 on the pituitary-hypothalamic axis. There were no significant changes in serum levels of prolactin, sex hormone-binding globulin (SHBG) or lipids. Side-effects were infrequent. Hot-flushes and sweats were not ...
The new 8-cpu Altix system, based on the Linux operating system and the Intel Itanium 2 processor, will support complex chemistry applications that are now becoming available on Linux platforms, and will do so with a shared memory model", explained AstraZenecas Jim Damewood, associate director, Chemistry, Computational Chemistry & Informatics, whose department has used SGI technologies for the last 15 years. "This technology delivers the benefits of the modular Linux approach coupled with the ability to dedicate all processors to the same complex task simultaneously.". The shared memory architecture of SGI Origin and Altix servers and superclusters enables all processors within a system to tackle the same problem together, while the alternative distributed computing model requires tasks to be broken up into smaller jobs to be addressed by just a subset of processors. "The Origin server upgrade, installed in June, has expanded our high performance computing capacity to 64 processors", added Jim ...
Protoplasma. 2010 Oct;246(1-4):101-7. Epub 2010 Aug 17. Jodłowska-Jedrych B, Jedrych M, Matysiak W. Source Department of Histology and Embryology, Medical University of Lublin, Radziwiłłowska 11, 20-080, Lublin, Poland. [email protected] Abstract The zona pellucida (ZP) is an external glycoprotein membrane of oocytes of mammals and embryos in the early stage of their development. ZP first appears in growing ovarian follicles as an extracellular substance between the oocyte and granular cells. The zona pellucid markedly affects the development and maturation of the oocyte. The morphology of the ZP-oocyte complex allows a more precise determination of the oocyte maturity. According to numerous experimental studies, ZP is essential for preimplantation embryonic development of humans and other mammals. It prevents dispersion of blastomeres and enhances their mutual interactions. ZP is a dynamic structure responsible for the provision of nutrients to early forms of oocytes in mammals. The aim of ...
NEOMED and the Institute for Research in Immunology and Cancer - Commercialisation of Research (IRICoR) have entered today into a strategic collaboration to accelerate the development and transfer of promising drug candidates between academia and the biopharmaceutical industry. The organisations will use their complementary strengths and capabilities in the value chain going from target identification to human proof-of-concept to deliver potential therapies for unmet medical needs. NEOMED and IRICoR will allow access to each others state-of-the-art facilities, equipment, expertise and resources to advance jointly selected projects.. "With this partnership, we will leverage our respective strengths to build robust projects and deliver strong and high quality candidate drugs with potential to treat diseases in multiple therapy areas," said Dr. Philippe Walker, Chief Scientific Officer of NEOMED. "IRICoR has established a very strong High Throughput Screening platform and medicinal chemistry ...
Estrobin, also known as α,α-di(p-ethoxyphenyl)-β-phenylbromoethylene and commonly abbreviated as DBE, is a synthetic, nonsteroidal estrogen of the triphenylethylene group that was never marketed.[1][2] Chlorotrianisene, and subsequently clomifene and tamoxifen, were derived from it.[1][2] Estrobin, similarly to other triphenylethylenes, is very lipophilic and hence very long-lasting in its duration of action.[1][2] Similarly to chlorotrianisene, estrobin behaves a prodrug to a much more potent estrogen in the body.[2] ...
Most preclinical studies that aim to prove the antistroke efficacy of candidate drugs are performed in experimental settings bearing little-if any-resemblance to clinical reality, which is a possible reason for several neuroprotective drug failures (36,37). Potential causes of this lack of success include use of preclinical drug administration paradigms not achievable at the clinic level (e.g., drug administration before or very shortly after stroke, intracerebroventricular injections, and too-high doses of the candidate drugs (38)), efficacy experiments performed using animal models that lack common comorbidities of stroke patients, such as diabetes and hypertension (36), and finally, nearly all rodent stroke studies are performed in young animals, whereas most stroke patients are elderly (39).. Our goal in the current study was to determine the potential antistroke efficacy of a DPP-4 inhibitor therapy by mimicking the likely clinical scenario of an obese type 2 diabetic patient receiving this ...
TY - JOUR. T1 - Mifepristone regulates expression of apoptosis related genes Fas and FasL in mouse endometrium. AU - Gao, F.. AU - Xu, F. H.. AU - Zhou, X. C.. AU - Han, X. B.. AU - Liu, Y. X.. PY - 2001/7/3. Y1 - 2001/7/3. N2 - AIM: To investigate the anti-implantation mechanism of mifepriston. METHODS: In situ hybridization and immunohistochemistry were applied to determine mRNA and protein. RESULTS: After mifepriston injection, the number of implantation sites were obviously reduced, mifepriston could inhibit the embryo implantation in mouse. The expression of apoptosis related genes, Fas and FasL, in mouse endometrium was also decreased after mifepriston treatment. CONCLUSION: The expression of apoptosis related genes Fas and FasL is regulated by mifepriston and the inhibitory effect of mifepriston on the embryo implantation may be mediated by action on the Fas/FasL system.. AB - AIM: To investigate the anti-implantation mechanism of mifepriston. METHODS: In situ hybridization and ...
A University of Otago study targeting the immune response to anti-oestrogen therapy is among three newly funded innovative research projects which share the goal of improving and ultimately ensuring breast cancer survival in New Zealand.
From BioPortfolio: SummaryAthera Biotechnologies AB Athera is a biopharmaceutical company that develops targeted anti inflammatory biological candidate drugs and companion diagnos...
Looking for online definition of genitoinguinal ligament in the Medical Dictionary? genitoinguinal ligament explanation free. What is genitoinguinal ligament? Meaning of genitoinguinal ligament medical term. What does genitoinguinal ligament mean?
Introduction and objective: The anticarcinogenic potential of milk fat can be attributed to its antioxidant, anti-inflammatory, immunostimulatory properties as well as the presence of compounds with antimutagenic effects. In view of the high incidence of cancer the aim of this article was to...
Quantifying DNA damage is mandatory to assess (i) potential adverse effects of candidate drugs, molecules or extracts developed in the dermo-cosmetic industry, and (ii) the efficacy of anticancer therapies, in order to induce tumor cell genotoxicity. Genotoxic potential effect can be analyzed by different assays, like
While searching for novel painkillers, researchers at KU Leuven in Belgium came to the surprising conclusion that some candidate drugs actually increase pain. In a study published in the journal Nature Chemical Biology, the ...
Researchers at the National Institutes of Health have identified a potential new drug that could help in the treatment of a form of Batten disease, a fatal childhood disorder. The researchers tested the drug in mice with the disease and found that it slowed the loss of coordination seen in the disorder, and extended the animals life span.
Cancer biology, signal transduction and pharmacogenomics, Biomarker discovery and screening of candidate drug molecules, Drug metabolism and pharmacokinetics of anti-cancer agents,
Producers of pharmaceuticals and biologics are challenged to become more efficient in discovering and developing candidate drugs while increasing manufacturing productivity and reducing costs. Advanced instrumental techniques and workflows can help to accelerate the development pipeline and optimize production processes.. Thermo Fisher Scientific has innovative solutions at every stage of the bio/pharmaceutical process, from discovery through to production and QC. Our deep understanding of the challenges faced by producers of medicines allows us to forge partnerships that more quickly deliver next-generation drugs to market.. ...
Isomerase Therapeutics is a drug discovery and development company based in Cambridge, UK, with particular expertise in the discovery and development of optimised microbial natural products. We offer a proven route to develop these hits into drugs via our unique biosynthetic medicinal chemistry services. We offer this bespoke biosynthetic engineering/semi-synthetic chemistry platform and drug discovery and development expertise on a FTE basis to partners looking for more than just a CRO. Isomerase Therapeutics can help you take your chosen natural product from an interesting hit to a high value candidate drug.
1988). "Results of multicentric trial of Centchroman". In Dhwan B. N., et al. Pharmacology for Health in Asia : Proceedings of ... "Centchroman". Reproductive Health Online. 2003. Retrieved 2009-08-29. Nelson, Anita L.; Cwiak, Carrie (2011). "Combined oral ... Ormeloxifene is a selective estrogen receptor modulator (SERM). Marketed as Centchroman, Centron, or Saheli, it is pill that is ... 1990). "Clinical evaluation of Centchroman: a new oral contraceptive". In Puri, Chander P., Van Look, Paul F. A. Hormone ...
... through blocking or removing the tubes may be accomplished through an open abdominal surgery, a laparoscopic approach, or a hysteroscopic approach.[16] Depending on the approach chosen, the patient will need to undergo local, general, or spinal (regional) anesthesia. The procedure may be performed either immediately after the end of a pregnancy, termed a "postpartum" or "postabortion tubal ligation", or more than six weeks after the end of a pregnancy, termed an "interval tubal ligation".[5] The steps of the sterilization procedure will depend on the type of procedure being used. (See Tubal ligation methods below.) If the patient chooses a postpartum tubal ligation, the procedure will further depend on the delivery method. If the patient delivers via Cesarean section, the surgeon will remove part or all of the fallopian tubes after the infant has been delivered and the uterus has been closed.[16] Anesthesia for the tubal ligation will be the same as that being used for the ...
The hormonal IUD is inserted in a similar procedure to the nonhormonal copper IUD, and can only be inserted by a qualified medical practitioner.[39] Before insertion, a pelvic exam is performed to examine the shape and position of the uterus. It is also recommended that patients be tested for gonorrhea and chlamydia prior to insertion, as a current STI at the time of insertion can increase the risk of pelvic infection.[61] However, if a person has been previously screened and there is no evidence of infection on examination insertion of the IUD does not need to be delayed.[62] During the insertion, the vagina is held open with a speculum, the same device used during a pap smear.[39] A grasping instrument is used to steady the cervix, the length of the uterus is measured for proper insertion, and the IUD is placed using a narrow tube through the opening of the cervix into the uterus.[39] A short length of monofilament plastic/nylon string hangs down from the cervix into the vagina. The string ...
For medical abortion prior to 12 weeks gestation, the World Heath Organization recommends mifepristone 200 mg by mouth followed 1-2 days later by misoprostol 800 mcg inside the cheek, vaginally, or under the tongue; misoprostol may be repeated to maximize success.[3] The success rate of mifepristone followed by misoprostol through 10 weeks pregnancy is 96.6%.[4] In another review of people up to 9 weeks gestation, mifepristone followed by various routs of misoprostol was associated with a successful abortion rate of over 95%; 1.1% experienced ongoing pregnancy.[5] Those who took misoprostol less than 24 hours after mifepristone had higher failures rates compared to women who waited 1-2 days. The National Abortion Federation (NAF) recommends a mifepristone and misoprostol combination regimen.[6] This is an option for people with gestations through 70 days. Mifepristone 200 mg is taken and followed by misoprostol 800 mcg buccally, vaginally, or sublingually 24 to 48 hours later. The early ...
... is a class of prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945 introduced in 1945. These are drugs which cannot be purchased over the counter without the prescription of a qualified doctor.The manufacture and sale of all drugs are covered under the Drugs and Cosmetics Act and Rules. It is revised at times based on the advice of the Drugs Technical Advisory Board, part of the Central Drugs Standard Control Organization[1] in the Ministry of Health and Family Welfare. The most recent schedule H (2006) lists 536 drugs from abacavir to zuclopenthixol.[2] However, enforcement of Schedule H laws in India is lax, compared to the more restrictive Schedule X, for which a mandatory documentation trail must be maintained.[3] ...
Ormeloxifene (Centchroman). Post-intercourse. *Emergency contraception (pills or copper IUD) (Ulipristal acetate ...
... (also ethinyl estradiol/levonorgestrel) is a combined birth control pill made up of ethinylestradiol, an estrogen and levonorgestrel a progestin.[2] It is used for birth control, symptoms of menstruation, endometriosis, and as emergency contraception.[1][2] It is taken by mouth.[1] Side effects can include nausea, headache, blood clots, breast pain, depression, and liver problems.[2] Use is not recommended during pregnancy, the initial three weeks after childbirth, and in those at high risk of blood clots.[2] However, it may be started immediately after a miscarriage or abortion.[3] Smoking while using combined birth control pills is not recommended.[1] It works by stopping ovulation, making the mucus at the opening to the cervix thick, and making the uterus not suitable for implantation.[1] Ethinylestradiol/levonorgestrel has been approved for medical use in the United States at least since 1982.[1] It is on the World Health Organization's List of Essential ...
Ormeloxifene (Centchroman). Post-intercourse. *Emergency contraception (pills or copper IUD) (Ulipristal acetate ...
All contain an estrogen, ethinylestradiol or mestranol,[1][2] in varying amounts, and one of a number of different progestogens. (Regarding the estrogen, the inactive 3-methyl ether of ethinylestradiol, which must be metabolized by the liver into the active ethinylestradiol; 50 µg of mestranol is equivalent to only 35 µg of ethinylestradiol and should not be used when high-dose [50 µg ethinylestradiol] estrogen pills are needed; mestranol was the estrogen used in the first oral contraceptive, Enovid). They are usually taken for 21 days with then a seven-day gap during which a withdrawal bleed (often, but incorrectly, referred to as a menstrual period) occurs. These differ in the amount of estrogen given, and whether they are monophasic (the same dose of estrogen and progestogen during each of the 21 days) or multiphasic (varying doses). The introduction of extended-cycle monophasic pills (i.e. Seasonale) has shown that the withdrawal bleeding intervals can be decreased. ...
The first CIC to be studied was estradiol valerate/hydroxyprogesterone caproate (EV/OHPC) in 1963, and the second CIC to be studied was estradiol enantate/algestone acetophenide (E2-EN/DHPA) in 1964.[18][17] In 1967, E2-EN/DHPA was in the late stages of clinical development.[25][18] By 1969, the medication was available for medical use under the brand name Perlutal.[26] Within a few years, it was marketed under other brand names such as Topasel and Ova-Repos as well.[27][28][29][30] In addition, several other CICs had been introduced for medical use by 1972.[30] By 1976, two major CICs were in use: E2-EN/DHPA (brand names Perlutan, Topasel) in Spain and Latin America, and EV/OHPC (brand name Injectable No. 1) in China.[31] These CICs have been described as first-generation CICs.[31] Two second-generation CICs, estradiol cypionate/medroxyprogesterone acetate (EC/MPA; brand names Cyclofem and later Lunelle) and estradiol valerate/norethisterone enantate (EV/NETE; brand name Mesigyna), were ...
Some American legislators have unsuccessfully attempted to provide financial incentives to women on welfare who agree to use Norplant. For example, in Kansas, Republican Kerry Patrick introduced legislation that would grant welfare recipients a one-time payment of $500 to use Norplant, followed by a $50 bonus each year the implants remained in place."[30] Some judges have offered Norplant implants as a voluntary alternative to jail time for certain women convicted of child abuse or drug abuse during pregnancy. Two days after the 1990 FDA approval of Norplant, an editorial in The Philadelphia Inquirer suggested reducing the size of the black underclass by offering welfare mothers increased benefits if they agreed to use Norplant.[30][31] Eleven days later the Inquirer apologized for their "misguided and wrongheaded" editorial and for their suggestion of offering incentives for Norplant use.[30][32] Critics such as the ACLU argued that such uses are coercive and discriminatory, and compared such ...
... , also known as progesterone-only vaginal ring, is a form of vaginal ring used for birth control when breastfeeding.[1] Use can begin at four weeks and continue for at least up to a year following childbirth.[4][3] Failure rates with usual use is about 1.5 per 100 women.[1] It is used within the vagina with one ring lasting three months.[4] The woman is able to place and remove the ring herself.[3] Side effects include vaginal discharge and pain with urination.[3] It does not appear to be associated with serious side effects.[3][5] With use menstrual periods often do not resume.[1] It was specifically made for use with breastfeeding as it does not affect milk production.[1] It works by gradually releasing the hormone progesterone.[1] Progesterone vaginal rings have been approved for medical use since 1998.[2] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[6] As of 2014 they are ...
see Combined oral contraceptive pill § Role of Placebo Pills Puri V (1988). "Results of multicentric trial of Centchroman". In ... Nityanand S (1990). "Clinical evaluation of Centchroman: a new oral contraceptive". In Puri CP, Van Look PF. Hormone ...
Singh MM (2001). "Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone- ... Ormeloxifene, also known as centchroman, is one of the selective estrogen receptor modulators, or SERMs, a class of medication ... Dhar A, Srivastava A (June 2007). "Role of centchroman in regression of mastalgia and fibroadenoma". World J Surg. 31 (6): 1178 ... Singh, M.M. (2001). "Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone ...
Dhar A, Srivastava A (June 2007). "Role of centchroman in regression of mastalgia and fibroadenoma". World Journal of Surgery. ...
Puri V (1988). "Results of multicentric trial of Centchroman". In Dhwan B. N.; et al. Pharmacology for Health in Asia : ... Nityanand S (1990). "Clinical evaluation of Centchroman: a new oral contraceptive". In Puri, Chander P.; Van Look; Paul F. A. ...
Ormeloxifene (Centchroman). Post-intercourse. *Emergency contraception (pills or copper IUD) (Yuzpe regimen ...
... centchroman MeSH D03.438.150.266 --- chromones MeSH D03.438.150.266.300 --- cromolyn sodium MeSH D03.438.150.266.450 --- ... centchroman MeSH D03.830.219.266 --- chromones MeSH D03.830.219.266.300 --- cromolyn sodium MeSH D03.830.219.266.450 --- ...
Why buy Saheli 30mg (Centchroman)?. Saheli contains Centchroman as its active ingredient. Centchroman is the worlds first non- ... How to use Saheli 30mg (Centchroman)?. The usual recommended dose of Saheli 30mg (Centchroman) is two tablets in a week for 3 ... How does Saheli 30mg (Centchroman) work?. Saheli 30mg (Centchroman) is a non-steroidal contraceptive pill with a weak ... Saheli 30mg (Centchroman). $32.00. Saheli 30mg is an oral contraceptive pill. It is prescribed for women for the prevention of ...
Front Biosci (Elite Ed). 2018 Jan 01;10:1-14 Authors: Kamboj VP, Ray S, Anand N Abstract Centchroman (INN: Ormeloxifene), a ... Centchroman: A safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders. ... Centchroman: A safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders.. *. ... Thus, Centchroman is likely to show other curative and prophylactic activity in a wide range of other disorders. PMID: 28930603 ...
To study the effect of centchroman, a non-steroidal oral contraceptive, coadministration on the pharmacokinetics of metformin ... Keywords: Centchroman , drug interaction , metformin , oral antidiabetic , oral contraceptive Full-Text Cite this paper Add to ... Following centchroman coadministration, metformin showed significantly (P < 0.05) higher C max (C max 1, 3.96 ± 0.55 μg/ml and ... Conclusions : The results indicate that centchroman coadministration increases the rate but not the extent of absorption of ...
Centchroman. Centchroman is a Selective Estrogen Receptor Modulator, or SERM. It causes ovulation to occur asynchronously with ...
Clinical pharmacology studies with Centchroman. Indian Journal of Experimental Biology. 1977 Dec; 15(12): 1170-2. ...
Anand N, Ray S. Centchroman--a post-coital contraceptive agent. Indian Journal of Experimental Biology. 1977 Dec; 15(12): 1142- ...
Chrinic toxicity studies of Centchroman in rats & rhesus monkeys.. Authors: Mukerjee, S S. Sethi, N. Srivastava, G N. Roy, A K ... Chrinic toxicity studies of Centchroman in rats & rhesus monkeys. Indian Journal of Experimental Biology. 1977 Dec; 15(12): ...
Tubal ligation through blocking or removing the tubes may be accomplished through an open abdominal surgery, a laparoscopic approach, or a hysteroscopic approach.[16] Depending on the approach chosen, the patient will need to undergo local, general, or spinal (regional) anesthesia. The procedure may be performed either immediately after the end of a pregnancy, termed a "postpartum" or "postabortion tubal ligation", or more than six weeks after the end of a pregnancy, termed an "interval tubal ligation".[5] The steps of the sterilization procedure will depend on the type of procedure being used. (See Tubal ligation methods below.) If the patient chooses a postpartum tubal ligation, the procedure will further depend on the delivery method. If the patient delivers via Cesarean section, the surgeon will remove part or all of the fallopian tubes after the infant has been delivered and the uterus has been closed.[16] Anesthesia for the tubal ligation will be the same as that being used for the ...
The hormonal IUD is inserted in a similar procedure to the nonhormonal copper IUD, and can only be inserted by a qualified medical practitioner.[39] Before insertion, a pelvic exam is performed to examine the shape and position of the uterus. It is also recommended that patients be tested for gonorrhea and chlamydia prior to insertion, as a current STI at the time of insertion can increase the risk of pelvic infection.[61] However, if a person has been previously screened and there is no evidence of infection on examination insertion of the IUD does not need to be delayed.[62] During the insertion, the vagina is held open with a speculum, the same device used during a pap smear.[39] A grasping instrument is used to steady the cervix, the length of the uterus is measured for proper insertion, and the IUD is placed using a narrow tube through the opening of the cervix into the uterus.[39] A short length of monofilament plastic/nylon string hangs down from the cervix into the vagina. The string ...
For medical abortion prior to 12 weeks gestation, the World Heath Organization recommends mifepristone 200 mg by mouth followed 1-2 days later by misoprostol 800 mcg inside the cheek, vaginally, or under the tongue; misoprostol may be repeated to maximize success.[3] The success rate of mifepristone followed by misoprostol through 10 weeks pregnancy is 96.6%.[4] In another review of people up to 9 weeks gestation, mifepristone followed by various routs of misoprostol was associated with a successful abortion rate of over 95%; 1.1% experienced ongoing pregnancy.[5] Those who took misoprostol less than 24 hours after mifepristone had higher failures rates compared to women who waited 1-2 days. The National Abortion Federation (NAF) recommends a mifepristone and misoprostol combination regimen.[6] This is an option for people with gestations through 70 days. Mifepristone 200 mg is taken and followed by misoprostol 800 mcg buccally, vaginally, or sublingually 24 to 48 hours later. The early ...
Schedule H is a class of prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945 introduced in 1945. These are drugs which cannot be purchased over the counter without the prescription of a qualified doctor.The manufacture and sale of all drugs are covered under the Drugs and Cosmetics Act and Rules. It is revised at times based on the advice of the Drugs Technical Advisory Board, part of the Central Drugs Standard Control Organization[1] in the Ministry of Health and Family Welfare. The most recent schedule H (2006) lists 536 drugs from abacavir to zuclopenthixol.[2] However, enforcement of Schedule H laws in India is lax, compared to the more restrictive Schedule X, for which a mandatory documentation trail must be maintained.[3] ...
Ormeloxifene (Centchroman). Post-intercourse. *Emergency contraception (pills or copper IUD) (Ulipristal acetate ...
Ethinylestradiol/levonorgestrel (also ethinyl estradiol/levonorgestrel) is a combined birth control pill made up of ethinylestradiol, an estrogen and levonorgestrel a progestin.[2] It is used for birth control, symptoms of menstruation, endometriosis, and as emergency contraception.[1][2] It is taken by mouth.[1] Side effects can include nausea, headache, blood clots, breast pain, depression, and liver problems.[2] Use is not recommended during pregnancy, the initial three weeks after childbirth, and in those at high risk of blood clots.[2] However, it may be started immediately after a miscarriage or abortion.[3] Smoking while using combined birth control pills is not recommended.[1] It works by stopping ovulation, making the mucus at the opening to the cervix thick, and making the uterus not suitable for implantation.[1] Ethinylestradiol/levonorgestrel has been approved for medical use in the United States at least since 1982.[1] It is on the World Health Organizations List of Essential ...
Ormeloxifene (Centchroman). Post-intercourse. *Emergency contraception (pills or copper IUD) (Ulipristal acetate ...
All contain an estrogen, ethinylestradiol or mestranol,[1][2] in varying amounts, and one of a number of different progestogens. (Regarding the estrogen, the inactive 3-methyl ether of ethinylestradiol, which must be metabolized by the liver into the active ethinylestradiol; 50 µg of mestranol is equivalent to only 35 µg of ethinylestradiol and should not be used when high-dose [50 µg ethinylestradiol] estrogen pills are needed; mestranol was the estrogen used in the first oral contraceptive, Enovid). They are usually taken for 21 days with then a seven-day gap during which a withdrawal bleed (often, but incorrectly, referred to as a menstrual period) occurs. These differ in the amount of estrogen given, and whether they are monophasic (the same dose of estrogen and progestogen during each of the 21 days) or multiphasic (varying doses). The introduction of extended-cycle monophasic pills (i.e. Seasonale) has shown that the withdrawal bleeding intervals can be decreased. ...
The first CIC to be studied was estradiol valerate/hydroxyprogesterone caproate (EV/OHPC) in 1963, and the second CIC to be studied was estradiol enantate/algestone acetophenide (E2-EN/DHPA) in 1964.[18][17] In 1967, E2-EN/DHPA was in the late stages of clinical development.[25][18] By 1969, the medication was available for medical use under the brand name Perlutal.[26] Within a few years, it was marketed under other brand names such as Topasel and Ova-Repos as well.[27][28][29][30] In addition, several other CICs had been introduced for medical use by 1972.[30] By 1976, two major CICs were in use: E2-EN/DHPA (brand names Perlutan, Topasel) in Spain and Latin America, and EV/OHPC (brand name Injectable No. 1) in China.[31] These CICs have been described as first-generation CICs.[31] Two second-generation CICs, estradiol cypionate/medroxyprogesterone acetate (EC/MPA; brand names Cyclofem and later Lunelle) and estradiol valerate/norethisterone enantate (EV/NETE; brand name Mesigyna), were ...
Some American legislators have unsuccessfully attempted to provide financial incentives to women on welfare who agree to use Norplant. For example, in Kansas, Republican Kerry Patrick introduced legislation that would grant welfare recipients a one-time payment of $500 to use Norplant, followed by a $50 bonus each year the implants remained in place."[30] Some judges have offered Norplant implants as a voluntary alternative to jail time for certain women convicted of child abuse or drug abuse during pregnancy. Two days after the 1990 FDA approval of Norplant, an editorial in The Philadelphia Inquirer suggested reducing the size of the black underclass by offering welfare mothers increased benefits if they agreed to use Norplant.[30][31] Eleven days later the Inquirer apologized for their "misguided and wrongheaded" editorial and for their suggestion of offering incentives for Norplant use.[30][32] Critics such as the ACLU argued that such uses are coercive and discriminatory, and compared such ...
Progesterone vaginal ring, also known as progesterone-only vaginal ring, is a form of vaginal ring used for birth control when breastfeeding.[1] Use can begin at four weeks and continue for at least up to a year following childbirth.[4][3] Failure rates with usual use is about 1.5 per 100 women.[1] It is used within the vagina with one ring lasting three months.[4] The woman is able to place and remove the ring herself.[3] Side effects include vaginal discharge and pain with urination.[3] It does not appear to be associated with serious side effects.[3][5] With use menstrual periods often do not resume.[1] It was specifically made for use with breastfeeding as it does not affect milk production.[1] It works by gradually releasing the hormone progesterone.[1] Progesterone vaginal rings have been approved for medical use since 1998.[2] It is on the World Health Organizations List of Essential Medicines, the most effective and safe medicines needed in a health system.[6] As of 2014 they are ...
Ormeloxifene (Centchroman). Ormeloxifene (Centchroman) is a selective oestrogen receptor modulator, or SERM. It causes ...
1988). "Results of multicentric trial of Centchroman". In Dhwan B. N., et al. Pharmacology for Health in Asia : Proceedings of ... "Centchroman". Reproductive Health Online. 2003. Retrieved 2009-08-29. Nelson, Anita L.; Cwiak, Carrie (2011). "Combined oral ... Ormeloxifene is a selective estrogen receptor modulator (SERM). Marketed as Centchroman, Centron, or Saheli, it is pill that is ... 1990). "Clinical evaluation of Centchroman: a new oral contraceptive". In Puri, Chander P., Van Look, Paul F. A. Hormone ...
Implantable Drug Delivery Systems For Centchroman. B. D Shenoy, N Udupa, Nagarajkumari ...
Effect of Centchroman administration in normospermic & oligospermic individuals. Effect of Centchroman administration in ... Centchroman / Adult Clinical aspect: Therapy Language: English Journal: Indian J Exp Biol Year: 1977 Type: Article ... Adult , Benzopyrans/therapeutic use , Centchroman/pharmacology , Humans , Male , Oligospermia/drug therapy , Spermatozoa/drug ...
Centchroman. A non-steroidal anti-fertility agent with anti-hormonal properties.. Alprenolol ...
Methods for reducing bone loss using centchroman derivatives. US5389646 *. Dec 30, 1993. Feb 14, 1995. Zymogenetics, Inc.. ... Method for inhibiting bone loss using centchroman derivatives. US5545409 *. Apr 5, 1994. Aug 13, 1996. Massachusetts Institute ...
Sharma N, Gupta A, Jha PK, Rajput P. Mastalgia cured! Randomized trial comparing centchroman to evening primrose oil (letter). ...
  • Direct effect of antiestrogens namely tamoxifen and centchroman in concentration of 1, 2.5, 5, 10 and 20 micrograms/ml in incubation medium was determined on motility and penetration ability of human spermatozoa. (bvsalud.org)
  • The distance travelled by spermatozoa treated with tamoxifen or centchroman in media was reduced by 30% and addition of estradiol along with antiestrogen reduced it to 50% compared to that of untreated spermatozoa. (bvsalud.org)
  • Centchroman was administered orally at a dose of 5 mg/kg and levamisole (2.5 mg/kg/ p.o) was used as standard drug. (bvsalud.org)
  • Effect of Centchroman administration in normospermic & oligospermic individuals. (bvsalud.org)
  • To investigate the effect of xy2004, a centchroman derivative, on the proliferation of MCF-7 cells and the mechanisms. (jove.com)
  • The effect of centchroman on the immune system was evaluated by using different experimental models such as carbon clearance test, cyclophosphamide induced neutropenia, neutrophil adhesion test, effect on serum immunoglobulins, mice lethality test and indirect haemagglutination test. (bvsalud.org)
  • Thus, Centchroman is likely to show other curative and prophylactic activity in a wide range of other disorders. (medworm.com)
  • The results show that both centchroman and tamoxifen possess estrogen agonistic as well as antagonistic properties and 130 K protein can be used as a marker protein to study estrogen action and for screening of antiestrogenic compounds in a primate model. (bvsalud.org)
  • Centchroman induces G0/G1 arrest and caspase-dependent apoptosis involving mitochondrial membrane depolarization in MCF-7 and MDA MB-231 human breast cancer cells. (qxmd.com)